A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Immunotherapy after bladder cancer surgery shows excellent cancer-free survival rateson May 15, 2022 at 3:35 am
Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high ...
- Bladder Cancer: Immunotherapy After Surgery Improves Cancer-Free Survival Rateson May 15, 2022 at 2:17 am
In patients with urothelial cancer of the bladder, immunotherapy after surgery helped decrease cancer recurrence.
- Domain Therapeutics Bags €39M to Block GCPRs in Cancer Immunotherapyon May 13, 2022 at 7:13 am
Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round ...
- High Cancer Cases All Across The Globe Will Propel The Global Cancer Immunotherapy Market In The Forecast Period Of 2022-2027on May 13, 2022 at 2:37 am
The new report by Expert Market Research titled, ‘Global Cancer Immunotherapy Market Report and Forecast 2022-2027, gives an in-depth analysis ...
- Cancer Immunotherapy Market Size Highlighting Recent Trends and Top Key Vendors (Roche, Pfizer, Eli Lilly, Bayer) | Foreseen Till 2029on May 12, 2022 at 11:16 pm
The Global Cancer Immunotherapy Market is growing at a healthy CAGR in the forecast period of 2022 to 2029. In this fast-paced industry, market research ...
- New Bladder Cancer Drugs: Immunotherapy and Antibody-Drug Conjugateson May 12, 2022 at 8:41 am
“Now, for the first time, we can offer a new immunotherapy to reduce recurrence. It’s a major advance.” Here’s how the other FDA-approved drugs help patients: Pembrolizumab can be given for locally ...
- UVA Health launches world's first focused ultrasound cancer immunotherapy centeron May 12, 2022 at 4:00 am
CHARLOTTESVILLE – UVA Health and the Charlottesville-based Focused Ultrasound Foundation Wednesday announced the launch of the Focused Ultrasound Cancer Immunotherapy Center, the world’s first center ...
- World's first Focused Ultrasound Cancer Immunotherapy Center could revolutionize cancer careon May 11, 2022 at 2:47 pm
UVA Health and the Charlottesville-based Focused Ultrasound Foundation today announced the launch of the Focused Ultrasound Cancer Immunotherapy Center, the world's first center dedicated specifically ...
- UVA Health, Focused Ultrasound Foundation partner to launch Focused Ultrasound Cancer Immunotherapy Centeron May 11, 2022 at 7:20 am
Combining immunotherapy with focused ultrasound – a game-changing soundwave technology – has been found to overcome existing limitations of immunotherapy and may open new fronts in the war against ...
via Bing News